Human CXCL13/BLC/BCA-1 Antibody | R&D Systems AF801 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human CXCL13/BLC/BCA-1 Antibody

catalog :

AF801

quantity :

100 ug (also 25 ug)

price :

519 USD

clonality :

polyclonal

host :

domestic goat

conjugate :

nonconjugated

reactivity :

human, mouse, rhesus macaque

application :

western blot, immunohistochemistry, immunocytochemistry, neutralization, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

more info or order :

R&D Systems product webpage

citations: 15

Reference
Di Modugno F, Di Carlo A, Spada S, Palermo B, D Ambrosio L, D Andrea D, et al. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. EBioMedicine. 2024;101:105003 pubmed publisher
Kren xe1 cs L, Kren xe1 cs D, Borb xe9 nyi Z, T xf3 th E, Nagy A, Piukovics K, et al. Comparison of Follicular Helper T-Cell Markers with the Expression of the Follicular Homing Marker CXCR5 in Peripheral T-Cell Lymphomas-A Reappraisal of Follicular Helper T-Cell Lymphomas. Int J Mol Sci. 2023;25: pubmed publisher
Pampusch M, Sevcik E, Quinn Z, Davey B, Berg J, Gorrell Brown I, et al. Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Front Immunol. 2023;14:1101446 pubmed publisher
El Shikh M, El Sayed R, Aly N, Prediletto E, Hands R, Fossati Jimack L, et al. Follicular dendritic cell differentiation is associated with distinct synovial pathotype signatures in rheumatoid arthritis. Front Med (Lausanne). 2022;9:1013660 pubmed publisher
Pierson S, Katz L, Williams R, Mumau M, Gonzalez M, Guzman S, et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun. 2022;13:7236 pubmed publisher
Uzzan M, Martin J, Mesin L, Livanos A, Castro Dopico T, Huang R, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022;28:766-779 pubmed publisher
He J, Xiong X, Yang H, Li D, Liu X, Li S, et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022;32:530-542 pubmed publisher
Ma Q, Chen Y, Qin Q, Guo F, Wang Y, Li D. CXCL13 expression in mouse 4T1 breast cancer microenvironment elicits antitumor immune response by regulating immune cell infiltration. Precis Clin Med. 2021;4:155-167 pubmed publisher
Phillips D, Matusiak M, Gutierrez B, Bhate S, Barlow G, Jiang S, et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun. 2021;12:6726 pubmed publisher
Li G, Guo J, Zheng Y, Ding W, Han Z, Qin L, et al. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. Mol Ther Oncolytics. 2021;22:507-517 pubmed publisher
van Dijk N, Gil Jimenez A, Silina K, Hendricksen K, Smit L, de Feijter J, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26:1839-1844 pubmed publisher
Bellamri N, Viel R, Morzadec C, Lecureur V, Joannes A, De Latour B, et al. TNF-α and IL-10 Control CXCL13 Expression in Human Macrophages. J Immunol. 2020;204:2492-2502 pubmed publisher
Kim H, Kim Y, Jeon Y, Yang W, Kwon J, Han J. Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8/A9 in lymph nodes of patients with adult-onset Still's disease. Sci Rep. 2019;9:7517 pubmed publisher
Liu C, Huang X, Werner M, Broering R, Ge J, Li Y, et al. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Front Immunol. 2017;8:323 pubmed publisher
Lee K, Spata M, Bayne L, Buza E, Durham A, Allman D, et al. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov. 2016;6:256-69 pubmed publisher

product information

brand :

R&D Systems

master code :

AF801

SKU :

AF801

product name :

Human CXCL13/BLC/BCA-1 Antibody

unit size :

100 ug (also 25 ug)

seo description :

The Human CXCL13/BLC/BCA-1 Antibody from R&D Systems is a goat polyclonal antibody to CXCL13/BLC/BCA-1. This antibody reacts with human,mouse,primate - macaca mulatta (rhesus macaque),rabbit,xenograft. The Human CXCL13/BLC/BCA-1 Antibody has been validated for the following applications: Immunohistochemistry,Bioassay,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry,Western Blot,Neutralization,Dual RNAscope ISH-IHC Compatible.

target :

CXCL13/BLC/BCA-1

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Polyclonal

concentration :

LYOPH

conjugate :

Unconjugated

dilution :

Western Blot 0.1 ug/mL, Immunohistochemistry 5-15 ug/mL, Neutralization 1-4 ug/mL, Dual RNAscope ISH-IHC 5-15 ug/mL

host :

Goat

immunogen :

E. coli -derived recombinant human CXCL13/BCA-1, Val23-Arg94, Accession # Q53X90

isotype :

IgG

purity :

Antigen Affinity-purified

species :

Human,Mouse,Primate - Macaca mulatta (Rhesus Macaque),Rabbit,Xenograft

specificity :

Detects CXCL13/BLC/BCA-1 in direct ELISAs and Western blots.

gene symbol :

CXCL13

endotoxin note :

<0.10 EU per 1 ╡g of the antibody by the LAL method.

top caption :

Chemotaxis Induced by CXCL13/BLC/BCA-1 and Neutralization by Human CXCL13/BLC/BCA-1 Antibody.

accessionNumbers :

Q53X90

applications :

Western Blot,Neutralization,Dual RNAscope ISH-IHC Compatible,Bioassay,Immunohistochemistry,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry

USD :

519 USD

alt names :

ANGIE, ANGIE2, B cell-attracting chemokine 1, B lymphocyte chemoattractant, BCA1, BCA-1, BCA1B-cell chemoattractant, BCA-1CXC chemokine BLC, B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1), BLC, BLCSmall-inducible cytokine B13, BLR1L, B-lymphocyte chemoattractant, chemokine (C-X-C motif) ligand 13, chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant), C-X-C motif chemokine 13, SCYB13, SCYB13B-cell-attracting chemokine 1, small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage